샘플 요청 목록

 카트 문의
시장보고서
상품코드
1787189

세계의 mRNA 합성 원료 시장

mRNA Synthesis Raw Materials
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 278 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 mRNA 합성 원료 시장은 2030년까지 20억 달러에 도달

2024년에 17억 달러로 추정되는 mRNA 합성 원료 세계 시장은 2024-2030년간 CAGR 2.5%로 성장하여 2030년에는 20억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 캡핑제는 CAGR 3.1%를 나타내고, 분석 기간 종료시에는 7억 1,130만 달러에 이를 것으로 예측됩니다. 뉴클레오티드 부문의 성장률은 분석 기간중 CAGR 2.7%로 추정됩니다.

미국 시장은 4억 6,780만 달러로 추정, 중국은 CAGR4.7%로 성장 예측

미국의 mRNA 합성 원료 시장은 2024년에 4억 6,780만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 3억 8,030만 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 4.7%로 추정됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 1.0%와 2.2%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 1.5%를 나타낼 전망입니다.

세계 mRNA 합성 원료 시장 - 주요 동향 및 촉진요인 정리

mRNA 합성 원료는 어떻게 치료제의 다음 경지를 촉진할 수 있을까?

mRNA 기반 기술의 급속한 발전으로 메신저 RNA(mRNA) 합성에 필수적인 고순도 및 확장 가능한 원료에 대한 수요가 증가하고 있습니다. 이러한 원료에는 뉴클레오티드, 효소, 캡핑 시약, 지질 나노입자(LNP) 등이 포함되며, 이들은 모두 mRNA 치료제 및 백신의 안정성, 유효성, 제조가능성을 보장하는 데 중요한 역할을 합니다. mRNA 백신 코로나19의 전례 없는 성공은 mRNA 기술의 혁신 가능성을 보여주며 암, 유전병, 감염성 질환 치료법 개발에 대한 투자에 박차를 가하고 있습니다. 기존의 생물학적 제제와 달리 mRNA 기반 의약품은 합성 원료에 의존하기 때문에 복잡한 세포 배양 시스템을 필요로 하지 않고 빠른 확장이 가능합니다. 개인 맞춤형 의료와 유전자 편집 치료의 급증은 연구자들이 단백질 발현과 면역 반응 조절을 강화하기 위해 mRNA 구조물을 최적화하기 위해 노력함에 따라 고품질 원료에 대한 수요를 더욱 증폭시키고 있습니다. 또한, mRNA 기반 연구가 백신뿐만 아니라 단백질 대체요법, 재생의료까지 확대되면서 적용 범위가 넓어졌고, 엄격한 품질관리와 규제에 부합하는 제조 공정이 요구되고 있습니다. 생명공학 기업 및 CDMO(위탁개발 및 제조수탁기관)들이 비용 효율성과 수율 높은 mRNA 생산 최적화를 위해 경쟁하는 가운데, 원료의 혁신, 순도 기준, 공급망 탄력성에 대한 관심이 그 어느 때보다 중요해지고 있습니다.

어떤 기술 혁신이 mRNA 합성 공급망을 재구성하고 있는가?

기술의 발전은 mRNA 생산에 필요한 원료의 합성과 최적화를 크게 변화시켜 효율성, 확장성, 규제 준수성을 향상시킬 수 있는 길을 열어주고 있습니다. 가장 중요한 돌파구 중 하나는 체외 전사(IVT) 공정의 최적화이며, 박테리오파지 RNA 중합효소를 이용한 효소 합성은 이중가닥 RNA(dsRNA)의 혼입을 최소화하고 더 높은 mRNA 순도를 얻을 수 있도록 미세 조정되어 왔습니다. 효소적 캡핑 및 CleanCap(R) 기술을 이용한 공동 전사 캡핑과 같은 개선된 캡핑 전략으로 mRNA의 안정성과 번역 효율을 향상시켰습니다. 또한, N1-메틸슈도우리딘과 같은 화학적 변형 뉴클레오티드의 기술 혁신은 치료 효과를 향상시키는 동시에 면역원성을 현저히 감소시키고 있습니다. 지질 나노입자(LNP) 전달 시스템도 큰 진전을 이루었으며, 이온화 가능한 지질은 더 높은 생체적합성, 표적 조직으로의 전달, 표적 외 영향 감소를 위해 설계되었습니다. 뉴클레오시드 삼인산(NTP) 합성 및 정제의 자동화는 배치 간 일관성을 개선하고 생산 병목현상을 줄여 대규모 mRNA 생산을 가능하게 했습니다. 또한, 제형 설계에 AI 기반 예측 모델링을 통합함으로써 다양한 치료 용도를 위한 mRNA 구조물의 신속한 최적화가 가능해졌습니다. 이러한 기술적 개선으로 mRNA의 수율, 안정성, 전달이 한 번에 개선되어 연구기관과 제약사 모두 증가하는 수요에 원료가 안정적으로 대응할 수 있게 되었습니다.

mRNA 원료 생산에 규제 당국의 감시와 공급망 강건성이 필수적인 이유는 무엇일까?

mRNA 치료제 산업의 급속한 확장으로 원료 조달 및 생산에 대한 규제 당국의 감독과 공급망 안정성의 중요성이 커지고 있습니다. FDA, EMA 등 규제기관은 mRNA 합성에 사용되는 원료의 순도, 일관성, 추적성에 대한 가이드라인을 엄격하게 적용하고 있으며, GMP(Good Manufacturing Practice)를 철저히 준수하도록 하고 있습니다. 따라서 특히 뉴클레오티드, 캡핑 시약, 지질 부형제의 조달 및 정제에서 엄격한 품질 관리 대책이 필요합니다. 일회용 바이오프로세싱 기술의 채택이 증가함에 따라 제조 워크플로우가 간소화되고, 교차 오염의 위험이 감소하며, 고처리량 mRNA 생산의 효율성이 향상되고 있습니다. 그러나 mRNA 원료의 세계 공급망은 코로나19 팬데믹 기간 동안 주요 시약과 지질 부족으로 백신 생산이 지연된 것처럼 여전히 혼란에 취약한 상태입니다. 이에 제약사들은 지정학적 리스크와 물류 병목현상을 완화하기 위해 수직통합형 공급망에 대한 투자 및 지역 제조허브 설립을 추진하고 있습니다. 또한, 생명공학 기업과 화학물질 공급업체와의 제휴가 강화되어 고품질 mRNA 전구체 전용 생산시설 설립으로 이어지고 있습니다. mRNA 기반 백신 및 치료제에 대한 세계 수요가 지속적으로 증가하는 가운데, 이 획기적인 기술의 모멘텀을 지속하기 위해서는 탄력적이고 규정을 준수하는 공급망을 확보하는 것이 가장 중요합니다.

mRNA 합성 원료 시장을 촉진하는 주요 성장 요인은 무엇인가?

mRNA 합성 원료 시장의 성장은 mRNA 기반 치료제의 확대, 생명공학 연구 개발에 대한 투자 증가, 원료 정제 및 제형화 기술의 발전 등 여러 요인에 의해 주도되고 있습니다. mRNA 백신의 성공은 암 면역치료, 희귀질환 치료, 단백질 대체요법 등 새로운 용도 연구에 박차를 가하고 있으며, 이 모든 분야에서 발현과 안정성을 최적화할 수 있는 특수한 원료가 필요합니다. mRNA 기반 약물을 포함한 임상시험의 급증으로 고순도 뉴클레오티드, 효소 시약, 지질 캐리어에 대한 수요도 증가하고 있으며, 공급업체들은 생산 능력을 확대해야 하는 상황에 처해 있습니다. 또한, 자가 증폭 mRNA(saRNA) 및 순환 RNA(circRNA) 기술의 출현은 기술 혁신의 새로운 길을 열어 새로운 원료 구성의 필요성을 촉진하고 있습니다. mRNA 제제 개발에서 AI 기반 약물 설계와 하이스루풋 스크리닝의 채택이 확대되면서 정밀 엔지니어링 원료에 대한 수요가 더욱 가속화되고 있습니다. 또한, 백신 제조의 세계 분산화와 핵산 치료제 전문 CDMO의 등장으로 공급망이 강화되어 mRNA 전구체의 신속한 생산과 공급이 가능해졌습니다. mRNA 치료를 환자 개개인에 맞춘 맞춤 의료에 대한 관심이 높아지면서, 변형된 뉴클레오티드와 지질 캐리어의 맞춤형 합성이 요구되고 있는 것도 시장 확대에 기여하고 있습니다. 정부 및 제약회사가 팬데믹 대응 및 차세대 백신에 대한 투자를 지속하는 가운데, 고품질, 확장성, 규제 준수 mRNA 원료에 대한 수요는 지속적으로 증가할 것으로 예상되며, 현대 바이오테크놀러지의 핵심 역할을 확고히 하고 있습니다.

부문

제품 유형(캡핑제, 뉴클레오티드, 플라스미드 DNA, 효소, 기타 유형), 용도(백신 제조 용도, 치료제 제조 용도, 기타 용도), 최종 용도(바이오의약품 및 제약 기업 최종 용도, CRO 및 CMO 최종 용도, 학술기관 및 연구기관 최종 용도)

조사 대상 기업 예

  • Aldevron
  • BioNTech SE
  • Bio-Synthesis Inc.
  • BOC Sciences
  • Creative Biogene
  • CureVac N.V.
  • Eurogentec
  • F. Hoffmann-La Roche Ltd.
  • HONGENE
  • Jena Bioscience GmbH
  • Lucigen Corporation
  • Maravai LifeSciences
  • Merck KGaA
  • Moderna, Inc.
  • New England Biolabs
  • Promega Corporation
  • Sigma-Aldrich(MilliporeSigma)
  • Thermo Fisher Scientific, Inc.
  • TriLink BioTechnologies
  • Yeasen Biotechnology(Shanghai) Co., Ltd.

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI툴에 의해서, 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 일반적인 LLM나 업계별 SLM 쿼리에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.08.18

Global mRNA Synthesis Raw Materials Market to Reach US$2.0 Billion by 2030

The global market for mRNA Synthesis Raw Materials estimated at US$1.7 Billion in the year 2024, is expected to reach US$2.0 Billion by 2030, growing at a CAGR of 2.5% over the analysis period 2024-2030. Capping Agents, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$711.3 Million by the end of the analysis period. Growth in the Nucleotides segment is estimated at 2.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$467.8 Million While China is Forecast to Grow at 4.7% CAGR

The mRNA Synthesis Raw Materials market in the U.S. is estimated at US$467.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$380.3 Million by the year 2030 trailing a CAGR of 4.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.0% and 2.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR.

Global mRNA Synthesis Raw Materials Market - Key Trends & Drivers Summarized

How Are mRNA Synthesis Raw Materials Powering the Next Frontier of Therapeutics?

The rapid advancement of mRNA-based technologies has propelled the demand for high-purity and scalable raw materials essential for the synthesis of messenger RNA (mRNA). These raw materials include nucleotides, enzymes, capping reagents, and lipid nanoparticles (LNPs), all of which play a crucial role in ensuring the stability, efficacy, and manufacturability of mRNA therapeutics and vaccines. The unprecedented success of mRNA COVID-19 vaccines demonstrated the transformative potential of mRNA technology, spurring investments in developing treatments for cancer, genetic disorders, and infectious diseases. Unlike traditional biologics, mRNA-based drugs rely on synthetic raw materials, eliminating the need for complex cell culture systems and enabling rapid scalability. The surge in personalized medicine and gene editing therapies has further amplified the demand for high-quality raw materials, as researchers strive to optimize mRNA constructs for enhanced protein expression and immune response modulation. Additionally, the expansion of mRNA-based research beyond vaccines into protein replacement therapies and regenerative medicine has broadened the scope of applications, necessitating stringent quality controls and regulatory-compliant manufacturing processes. As biotechnology companies and CDMOs (Contract Development and Manufacturing Organizations) race to optimize cost-effective and high-yield mRNA production, the focus on raw material innovation, purity standards, and supply chain resilience has become more critical than ever.

What Technological Innovations Are Reshaping the mRNA Synthesis Supply Chain?

Technological advancements have significantly transformed the synthesis and optimization of raw materials required for mRNA production, paving the way for increased efficiency, scalability, and regulatory compliance. One of the most critical breakthroughs has been the optimization of in vitro transcription (IVT) processes, where enzymatic synthesis using bacteriophage RNA polymerases has been fine-tuned to yield higher mRNA purity with minimal double-stranded RNA (dsRNA) contaminants. Improved capping strategies, such as enzymatic capping and co-transcriptional capping using CleanCap® technology, have enhanced mRNA stability and translational efficiency. Additionally, innovations in chemically modified nucleotides, such as N1-methylpseudouridine, have significantly reduced immunogenicity while improving therapeutic efficacy. The lipid nanoparticle (LNP) delivery system has also undergone significant advancements, with ionizable lipids being engineered for greater biocompatibility, targeted tissue delivery, and reduced off-target effects. The automation of nucleoside triphosphate (NTP) synthesis and purification has improved batch-to-batch consistency, reducing production bottlenecks and enabling large-scale mRNA manufacturing. Furthermore, the integration of AI-driven predictive modeling in formulation design has facilitated rapid optimization of mRNA constructs for different therapeutic applications. These technological improvements have collectively enhanced mRNA yield, stability, and delivery, ensuring that raw materials meet the growing demands of both research institutions and pharmaceutical manufacturers.

Why Is Regulatory Oversight and Supply Chain Resilience Critical for mRNA Raw Material Production?

The rapid expansion of the mRNA therapeutics industry has heightened the importance of regulatory oversight and supply chain stability in the procurement and production of raw materials. Regulatory agencies such as the FDA and EMA have tightened guidelines for the purity, consistency, and traceability of raw materials used in mRNA synthesis, ensuring compliance with Good Manufacturing Practices (GMP). This has necessitated rigorous quality control measures, particularly in the sourcing and purification of nucleotides, capping reagents, and lipid excipients. The increasing adoption of single-use bioprocessing technologies has streamlined production workflows, reducing the risk of cross-contamination and improving efficiency in high-throughput mRNA manufacturing. However, the global supply chain for mRNA raw materials remains vulnerable to disruptions, as seen during the COVID-19 pandemic, when shortages of key reagents and lipids delayed vaccine production. This has prompted pharmaceutical companies to invest in vertically integrated supply chains and establish regional manufacturing hubs to mitigate geopolitical risks and logistical bottlenecks. Additionally, partnerships between biotech firms and chemical suppliers have intensified, leading to the establishment of dedicated production facilities for high-quality mRNA precursors. As global demand for mRNA-based vaccines and therapies continues to grow, ensuring a resilient and compliant supply chain will be paramount in sustaining the momentum of this groundbreaking technology.

What Are the Key Growth Drivers Propelling the mRNA Synthesis Raw Materials Market?

The growth in the mRNA synthesis raw materials market is driven by several factors, including the expansion of mRNA-based therapeutics, increasing investments in biotechnology R&D, and advancements in raw material purification and formulation technologies. The success of mRNA vaccines has fueled research into new applications, including cancer immunotherapy, rare disease treatments, and protein replacement therapies, all of which require specialized raw materials for optimized expression and stability. The surge in clinical trials involving mRNA-based drugs has also heightened the demand for high-purity nucleotides, enzymatic reagents, and lipid carriers, prompting suppliers to scale up production capabilities. Additionally, the emergence of self-amplifying mRNA (saRNA) and circular RNA (circRNA) technologies has opened new avenues for innovation, driving the need for novel raw material compositions. The growing adoption of AI-driven drug design and high-throughput screening in mRNA formulation development has further accelerated the demand for precision-engineered raw materials. Moreover, the global shift toward decentralized vaccine manufacturing and the rise of CDMOs specializing in nucleic acid therapeutics have strengthened the supply chain, enabling faster production and delivery of mRNA precursors. The increasing focus on personalized medicine, where mRNA therapies are tailored to individual patients, has also contributed to market expansion, necessitating custom synthesis of modified nucleotides and lipid carriers. As governments and pharmaceutical companies continue to invest in pandemic preparedness and next-generation vaccines, the demand for high-quality, scalable, and regulatory-compliant mRNA raw materials is expected to witness sustained growth, solidifying their role as a cornerstone of modern biotechnology.

SCOPE OF STUDY:

The report analyzes the mRNA Synthesis Raw Materials market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Capping Agents, Nucleotides, Plasmid DNA, Enzymes, Other Types); Application (Vaccine Production Application, Therapeutics Production Application, Other Applications); End-Use (Biopharmaceutical & Pharmaceutical Companies End-Use, CROs & CMOs End-Use, Academic & Research Institutes End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Aldevron
  • BioNTech SE
  • Bio-Synthesis Inc.
  • BOC Sciences
  • Creative Biogene
  • CureVac N.V.
  • Eurogentec
  • F. Hoffmann-La Roche Ltd.
  • HONGENE
  • Jena Bioscience GmbH
  • Lucigen Corporation
  • Maravai LifeSciences
  • Merck KGaA
  • Moderna, Inc.
  • New England Biolabs
  • Promega Corporation
  • Sigma-Aldrich (MilliporeSigma)
  • Thermo Fisher Scientific, Inc.
  • TriLink BioTechnologies
  • Yeasen Biotechnology (Shanghai) Co., Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • mRNA Synthesis Raw Materials - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Surge in mRNA Vaccine Development Drives Accelerated Demand for Raw Materials in mRNA Synthesis
    • Expanding Investment in Biotechnology and Pharmaceutical R&D Strengthens Market for mRNA Synthesis Raw Materials
    • Rising Need for mRNA-Based Therapeutics and Vaccines Expands Market Opportunities for Raw Material Suppliers
    • Technological Advancements in mRNA Synthesis Techniques Propel Demand for High-quality Raw Materials
    • Increasing Government Funding for mRNA Research and Vaccine Development Generates Growth in Raw Material Requirements
    • Expansion of mRNA Vaccine Manufacturing Capacity Strengthens Business Case for Scaling Raw Material Production
    • Rising Demand for Personalized Medicine and mRNA Therapies Expands Addressable Market for Synthesis Raw Materials
    • Regulatory Support and Accelerated Approval Processes for mRNA Vaccines Increase Raw Material Procurement and Usage
    • The Rise in Global Health Initiatives and Vaccination Programs Expands the Market for mRNA Synthesis Raw Materials
    • Advancements in Raw Material Purification and Synthesis Technologies Drive Efficiency and Cost Reduction in mRNA Production
    • Surge in mRNA-based COVID-19 Vaccine Production Fuels Long-term Demand for mRNA Synthesis Raw Materials
    • Growth in Research Institutions and Academic Labs Investing in mRNA Technology Propels Raw Material Demand
    • The Emergence of mRNA Therapies Beyond Vaccines Drives Innovation and Expands the Market for Specialized Raw Materials
    • Increasing Integration of mRNA Synthesis into Cancer Immunotherapy Research Expands Market Opportunity for Raw Materials
    • Expanding Production Facilities for mRNA-Based Products Strengthens Market for Essential Raw Materials in Large-scale Synthesis
    • Rising Demand for RNA Modifications and Specialized Reagents Drives New Opportunities for Raw Material Suppliers
    • Technological Innovation in Nucleotide Synthesis and Purification Enhances the Quality and Availability of mRNA Raw Materials
    • Growing Focus on Sustainable and Cost-effective mRNA Production Methods Expands Market for Raw Materials with Reduced Environmental Impact
    • Increasing Competitive Landscape Among Biopharma Companies Strengthens the Demand for Reliable and High-purity Raw Materials
    • Growing Collaboration Between mRNA Developers and Raw Material Providers Drives Long-term Supply Chain Stability and Innovation
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World mRNA Synthesis Raw Materials Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for mRNA Synthesis Raw Materials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Capping Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Capping Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Nucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Nucleotides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Plasmid DNA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Plasmid DNA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Enzymes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Enzymes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for CROs & CMOs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for CROs & CMOs End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Academic & Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Biopharmaceutical & Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Biopharmaceutical & Pharmaceutical Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Vaccine Production Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Vaccine Production Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Therapeutics Production Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Therapeutics Production Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • mRNA Synthesis Raw Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 34: Canada Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 36: Canada Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Canada 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • JAPAN
    • mRNA Synthesis Raw Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 40: Japan Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Japan 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 42: Japan Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Japan 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • CHINA
    • mRNA Synthesis Raw Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 46: China Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: China 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 48: China Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: China 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • EUROPE
    • mRNA Synthesis Raw Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for mRNA Synthesis Raw Materials by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • FRANCE
    • mRNA Synthesis Raw Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 58: France Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 60: France Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: France 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • GERMANY
    • mRNA Synthesis Raw Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 64: Germany Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 66: Germany Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Germany 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • ITALY
    • TABLE 70: Italy Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Italy 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 72: Italy Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Italy 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • UNITED KINGDOM
    • mRNA Synthesis Raw Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 76: UK Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: UK 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 78: UK Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: UK 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • SPAIN
    • TABLE 82: Spain Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Spain 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 84: Spain Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Spain 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • RUSSIA
    • TABLE 88: Russia Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Russia 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 90: Russia Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Russia 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 94: Rest of Europe Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of Europe 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 96: Rest of Europe Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Rest of Europe 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • ASIA-PACIFIC
    • mRNA Synthesis Raw Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 100: Asia-Pacific Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 101: Asia-Pacific 6-Year Perspective for mRNA Synthesis Raw Materials by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2025 & 2030
    • TABLE 102: Asia-Pacific Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Asia-Pacific 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 106: Asia-Pacific Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Asia-Pacific 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • AUSTRALIA
    • mRNA Synthesis Raw Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 108: Australia Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Australia 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 112: Australia Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Australia 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • INDIA
    • mRNA Synthesis Raw Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 114: India Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 115: India 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 118: India Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 119: India 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • SOUTH KOREA
    • TABLE 120: South Korea Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 121: South Korea 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 124: South Korea Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 125: South Korea 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 126: Rest of Asia-Pacific Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 130: Rest of Asia-Pacific Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 131: Rest of Asia-Pacific 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • LATIN AMERICA
    • mRNA Synthesis Raw Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 132: Latin America Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 133: Latin America 6-Year Perspective for mRNA Synthesis Raw Materials by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 136: Latin America Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 137: Latin America 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 138: Latin America Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 139: Latin America 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 142: Argentina Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 143: Argentina 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 144: Argentina Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 145: Argentina 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 148: Brazil Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 149: Brazil 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 150: Brazil Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 151: Brazil 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 154: Mexico Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 155: Mexico 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 156: Mexico Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 157: Mexico 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 160: Rest of Latin America Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 161: Rest of Latin America 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 162: Rest of Latin America Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 163: Rest of Latin America 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • MIDDLE EAST
    • mRNA Synthesis Raw Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East 6-Year Perspective for mRNA Synthesis Raw Materials by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2025 & 2030
    • TABLE 166: Middle East Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 167: Middle East 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 168: Middle East Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 169: Middle East 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • IRAN
    • TABLE 172: Iran Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 173: Iran 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 174: Iran Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 175: Iran 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • ISRAEL
    • TABLE 178: Israel Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 179: Israel 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 180: Israel Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 181: Israel 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • SAUDI ARABIA
    • TABLE 184: Saudi Arabia Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 185: Saudi Arabia 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 186: Saudi Arabia Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 187: Saudi Arabia 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 190: UAE Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 191: UAE 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 192: UAE Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 193: UAE 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 196: Rest of Middle East Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 197: Rest of Middle East 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 198: Rest of Middle East Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 199: Rest of Middle East 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • AFRICA
    • mRNA Synthesis Raw Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 202: Africa Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 203: Africa 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 204: Africa Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 205: Africa 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제